Does Palliative Chemotherapy Really Palliate?

Many patients believe that palliative chemo is curative treatment, so oncologists need to have important end-of-life discussions early in the course of cancer care.

Update on Supreme Court Gene Patent Ruling

Questions remain regarding the sequence-interpreting experience of the new crop of BRCA testing labs.

Enter Our April Contest and Win A Nike Fuel Band!

Become an Oncology Practice Pro by participating in this month's contest. Three lucky participants will win a Nike Fuel Band!

Streptococcus bovis and CRC

Presence of a particular biotype of the Streptococcus bovis bacterium can be an indicator of a GI malignancy.

SYLATRON® (peginterferon alfa-2b)

Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.

NEPA for Control of Chemo-induced Nausea and Vomiting

Palonosetron and netupitant combo showed superior efficacy in controlling nausea and vomiting compared with palonosetron alone.

Featured Videos


Latest News

Six Percent of CRCs Are Interval Tumors

Six percent of patients with colorectal cancer (CRC) have interval cancers, which develop within six to 60 months of colonoscopy.

Chemo Ups Survival in Bladder Cancer

The use of neoadjuvant and adjuvant chemotherapy for the treatment of muscle-invasive bladder cancer is associated with a survival benefit in the general population, and may be underutilized.

CRC Resection Morbidity, Mortality Higher for Elderly

Higher hospital charge and increased length of stay for patients aged 80 years and older post-resection

Viewpoints & Cases

Combo Therapy Better for Chemo-induced Nausea and Vomiting

Combo Therapy Better for Chemo-induced Nausea and Vomiting

Palonosetron and netupitant combo showed superior efficacy in controlling nausea and vomiting compared with palonosetron alone.

Ceritinib Demonstrates Strong Response in ALK-positive NSCLC

Ceritinib Demonstrates Strong Response in ALK-positive NSCLC

In a phase 1 study, the potent ALK inhibitor shows promise for treating NSCLC.

A 58-year-old with Stage IV Pancreatic Adenocarcinoma

A 58-year-old with Stage IV Pancreatic Adenocarcinoma

Chief Complaint

R.M. is a 58-year-old male recently diagnosed with stage IV pancreatic adenocarcinoma (Slide 1). He is a mechanical engineer ...

A 55-year-old Woman with Breast Cancer and Shortness of Breath

A 55-year-old Woman with Breast Cancer and Shortness of Breath

Chief Complaint

J.W. is a 55-year-old woman recently admitted to the hospital for worsening shortness of breath (Slide 1).

Relevant Medical History

• ...

From the Board

Expert Perspectives on Breast Cancer Awareness Month

Editorial Board Member Don Dizon, MD, answers some questions about issues in breast cancer treatment today.

Reflections on Patient Perspectives and Survivorship from the 2013 Breast Cancer Symposium

ChemotherapyAdvisor.com Editorial Board Member Don S. Dizon discusses survivorship issues from the 2013 Breast Cancer Symposium.

Editorial Advisory Board

 

Barbara Ann Burtness, MD

Steven Cohen, MD

E. David Crawford, MD

Don S. Dizon, MD, FACP

Jeffrey M. Farma, MD

Edith A. Perez, MD

Neal D. Shore, MD, FACS

Mark A. Socinski, MD

Martin Tallman, MD

Click here for complete profiles

Poll Question


News from Oncology Nurse Advisor

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs